Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Defence appoints Dr. Amie Phinney as president and CEO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. Amie Phinney, PhD, MBA, as president and CEO, effective August 1, 2026. Sébastien Plouffe, founder and CEO, will assume the position of executive...

August 6, 2026

Developments

Rise uplists to OTCQB; achieves DTC eligibility

Rise Nano Optics (CSE: EYE) (OTCQB: RNOLF) has announced that its common shares have been approved to commence trading on the OTCQB Venture Market and are also now DTC eligible, enhancing accessibility and efficiency of...

August 4, 2026

Developments

First site in Indiana offers Aclarion’s Nociscan for lower back pain

Aclarion (NASDAQ: ACON, ACONW) has announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology...

August 4, 2026

Developments

Elite launches generic Requip XL for Parkinson’s

Elite Pharmaceuticals (OTCQB: ELTP) has launched a generic version of Requip XL (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets, for the treatment of Parkinson’s...

August 4, 2026

Executive Moves

Michelle Gilson joins Rani BOD

Rani Therapeutics Holdings (NASDAQ: RANI) has announced the appointment of Michelle Gilson to its board of directors (BOD). Ms. Gilson will serve as chair of the audit committee. Most recently, Ms. Gilson served as...

August 4, 2026

Developments

Lucid starts Envoy Medical at buy; PT $2

Lucid Capital Markets initiated coverage of Envoy Medical (NASDAQ:COCH) with a “buy” rating and price target of $2.00. The stock closed at $0.66 on July 24. Envoy designs, manufactures, and is working to commercialize...

July 27, 2026

Developments

Incisionless TULSA Procedure for prostate cancer demonstrated statistically significant superior penile length preservation compared to Robotic Radical Prostatectomy at 1 month

The title of Profound Medical’s (NASDAQ:PROF; TSX:PRN) press release today, “Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial,” playfully set the tone for its reporting of a sensitive subject: penile...

July 24, 2026

Markets

Rodman & Renshaw starts Zentalis at buy; PT $11

Rodman & Renshaw initiated coverage of Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a “buy” rating and price target of $11.00. The stock closed at $4.50 on July 22. Zentalis is a clinical oncology innovator...

July 23, 2026

Executive Moves

Finance leader Dr. Neera Ravindran joins Unnatural Products as CFO

Closely held Unnatural Products (UNP) has announced the appointment of Neera Ravindran, MD, MBA, as chief financial officer (CFO). Dr. Ravindran brings more than 20 years of deep public markets and private company...

July 22, 2026

Developments

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Valion Bio (NASDAQ: VBIO) has announced that the regulatory dossier for its lead candidate, Entolimod for acute radiation syndrome (ARS), has been accepted by Ukraine’s Ministry of Health (MoH) for formal review...

July 22, 2026

Markets

Clear Street starts Equillium at buy; PT $9

Clear Street initiated coverage of Equillium (NASDAQ: EQ) with a “buy” rating and price target of $9.00. The stock closed at $2.47 on July 20. Equillium is a clinical-stage biotechnology company developing therapies...

July 21, 2026

Developments

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate...

July 20, 2026

Subscribe